Dr. Bauer on Rovalpituzumab Tesirine in Patients With SCLC

Todd Bauer, MD
Published: Tuesday, Jul 05, 2016


Todd Bauer, MD, associate director, Drug Development, principal investigator, Sarah Cannon Research Institute, discusses the safety and efficacy of single-agent rovalpituzumab tesirine (Rova-T), a delta-like protein 3-targeted antibody-drug conjugate in recurrent/refractory patients with small cell lung cancer (SCLC).

This agent is designed to have a novel approach in that it targets a specific receptor on top of cancer and stem cells prior to releasing a potent chemotherapeutic, Bauer explains. Data show that the agent can be administered safely. Additionally, after receiving a couple doses of treatment, patients are able to take a treatment holiday. If/when disease recurs, treatment can resume, he says.

This antibody-drug conjugate does not release its chemotherapeutic until it reaches the SCLC cells, Bauer adds. When this occurs, the cancer cells internalize and cell death takes place.

Todd Bauer, MD, associate director, Drug Development, principal investigator, Sarah Cannon Research Institute, discusses the safety and efficacy of single-agent rovalpituzumab tesirine (Rova-T), a delta-like protein 3-targeted antibody-drug conjugate in recurrent/refractory patients with small cell lung cancer (SCLC).

This agent is designed to have a novel approach in that it targets a specific receptor on top of cancer and stem cells prior to releasing a potent chemotherapeutic, Bauer explains. Data show that the agent can be administered safely. Additionally, after receiving a couple doses of treatment, patients are able to take a treatment holiday. If/when disease recurs, treatment can resume, he says.

This antibody-drug conjugate does not release its chemotherapeutic until it reaches the SCLC cells, Bauer adds. When this occurs, the cancer cells internalize and cell death takes place.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x